Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DV-601 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DV-601 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| DV-601 | DRUG | Six injections of DV-601 administered over a period of 12 weeks. |
| Entecavir | DRUG | Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration. |
Inclusion Criteria: * Male and female subjects 18 to 65 years of age. * Signed informed consent. * Diagnosis of CHB and candidates for therapy * Normal renal function * Women of childbearing potential must have a serum negative pregnancy test at screening. Women of childbearing potential and males ...
DV-601 is an investigational small molecule being developed for the treatment of chronic Hepatitis B. It is currently in Phase 1 clinical development and has been studied in a completed trial involving 14 subjects with chronic Hepatitis B.
DV-601 is being developed by Dynavax Technologies Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol DVAX. The drug is currently in Phase 1 clinical development for chronic Hepatitis B.
DV-601 is in Phase 1 clinical development. It has completed one Phase 1 trial, NCT01023230, which enrolled 14 subjects with chronic Hepatitis B. The drug is investigational and has not been approved by regulatory authorities.
DV-601 has been studied in one completed Phase 1 clinical trial, NCT01023230, titled 'A Study to Assess DV-601 in Subjects With Chronic Hepatitis B.' The trial enrolled 14 subjects in Poland and was not randomized, double-blind, or controlled.
Yes, DV-601 is a small molecule therapeutic. It is being developed by Dynavax Technologies Corporation for the treatment of chronic Hepatitis B, an infectious disease. The drug is currently in Phase 1 clinical development.